Armata Pharmaceuticals Company Description

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.

It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.

It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents.

The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.

Armata Pharmaceuticals, Inc.

Country	United States
Industry	Biological Products, Except Diagnostic Substances
Employees	60
CEO	Deborah Birx

Contact Details

Address: 5005 McConnell Avenue Los Angeles, Washington 90066 United States
Phone	310 665 2928
Website	armatapharma.com

Stock Details

Ticker Symbol	TG1N
Exchange	Frankfurt Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Deborah Birx	Chief Executive Officer
David House	Chief Financial Officer
Peter Hubbard	Chief Operating Officer